Elicio Therapeutics, Inc. Operating Cash Flow
Elicio Therapeutics, Inc. (ELTX) reported Operating Cash Flow of -$19.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$8.16M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$11.64M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.80M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$11.09M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$36.95M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$37.07M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$32.69M.
- Elicio Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$22.18M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$19.81M 10-Q · filed 2026-08-13 | -$26.61M derived: sum of 3 quarters · filed 2026-08-13 | -$37.69M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$11.64M 10-Q · filed 2026-05-11 | -$18.44M derived: sum of 2 quarters · filed 2026-05-11 | -$29.53M derived: sum of 3 quarters · filed 2026-05-11 | -$38.48M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$17.88M derived: sum of 2 quarters · filed 2026-03-12 | -$26.83M derived: sum of 3 quarters · filed 2026-08-13 | -$36.95M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$11.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$20.04M derived: sum of 2 quarters · filed 2026-08-13 | -$30.16M 10-Q · filed 2025-11-13 | -$38.90M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$8.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$19.07M 10-Q · filed 2026-08-13 | -$27.81M derived: sum of 3 quarters · filed 2026-08-13 | -$35.09M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$10.12M 10-Q · filed 2026-05-11 | -$18.86M derived: sum of 2 quarters · filed 2026-05-11 | -$26.14M derived: sum of 3 quarters · filed 2026-05-11 | -$35.06M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$16.02M derived: sum of 2 quarters · filed 2026-03-12 | -$24.95M derived: sum of 3 quarters · filed 2026-03-12 | -$37.07M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$7.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$16.20M derived: sum of 2 quarters · filed 2025-11-13 | -$28.32M 10-Q · filed 2025-11-13 | -$38.22M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$8.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$21.05M 10-Q · filed 2025-08-07 | -$30.95M derived: sum of 3 quarters · filed 2025-08-07 | -$36.13M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$12.12M 10-Q · filed 2025-05-13 | -$22.02M derived: sum of 2 quarters · filed 2025-05-13 | -$27.20M derived: sum of 3 quarters · filed 2025-05-13 | -$36.68M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$15.08M derived: sum of 2 quarters · filed 2025-03-31 | -$24.55M derived: sum of 3 quarters · filed 2025-03-31 | -$32.69M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$5.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$14.66M derived: sum of 2 quarters · filed 2024-11-13 | -$22.80M 10-Q · filed 2024-11-13 | -$22.80M 10-Q · filed 2023-11-13 | -$30.07M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | -$9.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$17.61M 10-Q · filed 2024-08-13 | -$24.89M derived: sum of 3 quarters · filed 2024-08-13 | -$30.28M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$8.14M 10-Q · filed 2024-05-15 | -$8.08M 10-Q · filed 2023-05-10 | -$15.41M derived: sum of 2 quarters · filed 2024-05-15 | -$20.80M derived: sum of 3 quarters · filed 2024-05-15 | -$14.66M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$12.66M derived: sum of 2 quarters · filed 2024-03-29 | -$6.53M derived: sum of 3 quarters · filed 2024-03-29 | -$22.18M 10-K · filed 2024-03-29 | -$38.39M 10-K · filed 2023-03-17 | |||
| 2022-09-30 | -$5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $750.00K derived: sum of 2 quarters · filed 2023-11-13 | -$14.90M 10-Q · filed 2023-11-13 | -$33.96M 10-Q · filed 2022-11-14 | -$29.27M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $6.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.52M 10-Q · filed 2023-08-14 | -$25.56M 10-Q · filed 2022-08-15 | -$23.88M derived: sum of 3 quarters · filed 2023-08-14 | -$39.08M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$15.65M 10-Q · filed 2023-05-10 | -$30.02M derived: sum of 2 quarters · filed 2023-05-10 | -$45.21M derived: sum of 3 quarters · filed 2023-05-10 | -$55.74M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$14.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$29.56M derived: sum of 2 quarters · filed 2023-03-17 | -$40.09M derived: sum of 3 quarters · filed 2023-03-17 | -$52.64M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$15.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$25.73M derived: sum of 2 quarters · filed 2022-11-14 | -$38.28M 10-Q · filed 2022-11-14 | -$17.69M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$10.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$23.08M 10-Q · filed 2022-08-15 | -$2.49M derived: sum of 3 quarters · filed 2022-08-15 | -$24.43M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$12.55M 10-Q · filed 2022-05-16 | $8.04M derived: sum of 2 quarters · filed 2022-05-16 | -$13.90M derived: sum of 3 quarters · filed 2022-05-16 | -$26.71M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $20.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$1.35M derived: sum of 2 quarters · filed 2022-03-30 | -$14.15M derived: sum of 3 quarters · filed 2022-03-30 | -$22.89M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | -$21.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$34.75M derived: sum of 2 quarters · filed 2021-11-12 | -$43.48M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$12.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$21.54M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$8.73M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |